You are here


July 21, 2017
MHRP and Collaborators at the 9th IAS Conference on HIV Science

MHRP researchers and collaborators are scheduled to speak and present at the 9th IAS Conference on HIV Science taking place July 23-26 in Paris.

MHRP Researchers Speaking in Special Sessions:

Sunday, July 23

IAS HIV Cure & Cancer forum

10:30-12:00 - Panelist Dr. Jintanat Anaworanich, "Clinical Trial Design and Participation"

Monday, July 24

2:30 - 5:00 -...

July 11, 2017
Initiating ART During Acute HIV Infection Affects Trajectory of Viral Load

In a study comparing viral load in individuals during acute HIV infection, those who began antiretroviral therapy (ART) immediately had dramatically lower viral loads compared to those who did not immediately begin therapy. Findings from the study were published last week in the Journal of the International AIDS Society.

The extent of viral replication during acute HIV infection (AHI)...

July 7, 2017
Diagnosis of Acute HIV Infection and Immediate Treatment Reduces Transmission by 89% in Thai Cohort

A new study conducted by the Thai Red Cross and the U.S. Military HIV Research Program (MHRP) has shown that detecting HIV during acute infection and immediately initiating antiretroviral therapy (ART) was associated with an estimated 89% reduction in HIV transmission in a Thai cohort compared to those who receive no intervention during acute infection. Findings from the study were published...

July 6, 2017
Characterization of T Cells Infected with Simian Immunodeficiency Virus Reveals Host-pathogen Interactions

HIV and its simian counterpart, SIV, infect and kill CD4 T cells in the immune system, resulting in a massive depletion that ultimately leads to AIDS in the absence of antiretroviral therapy (ART). With effective therapy, CD4 T cells are largely preserved, but some harbor latent virus that can persist for decades and reemerge when ART is interrupted, presenting a hurdle to curing HIV.


June 20, 2017
Late HIV Vaccine Boost Elicits Higher Immune Response in Volunteers from the RV144 Thai Trial

The Army-led RV144 HIV vaccine trial provided the first evidence in humans that a safe and effective preventive HIV vaccine is possible. A new study has shown that boosting RV144 volunteers 6-8 years later with AIDSVAX B/E vaccine resulted in higher immune responses than were seen immediately after RV144.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the...

May 3, 2017
Dual-use Heroin Vaccine Elicits Immune Response in Mice

A novel combination vaccine designed to treat heroin addiction and target HIV was found to elicit immune responses in mice and dull their response to injected heroin in a recent preclinical trial. Findings from the study were published today in the online journal npj Vaccines.

A team of U.S. government researchers led by scientists from the Walter Reed Institute of Research (WRAIR)...

April 21, 2017
Dr. Carl Alving Inducted as National Academy of Inventors Fellow

Earlier this month, Dr. Carl Alving, MHRP’s Chief of Adjuvant and Antigen Research, was inducted as a 2016 Fellow of the National Academy of Inventors (NAI) in a ceremony at the Kennedy Library and Museum in Boston.

NAI elects as Fellows academic inventors who have “demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible...

March 30, 2017
Clinical Training Course in Liberia Boosts Biopreparedness Efforts in West Africa

The Joint West Africa Research Group (JWARG) is holding a week-long clinical course in tropical and emerging infectious diseases for clinicians and lab professionals in Monrovia, Liberia. This training will help strengthen clinical skills needed to enhance research capability in West Africa. The 2014 Ebola epidemic highlighted gaps in local and regional disease data, research capabilities, and...

March 24, 2017
World TB Day: MHRP Research Physician Focuses on Problem of TB/HIV Co-infection

HIV and tuberculosis (TB) are a deadly combination.  TB is the leading cause of death among individuals living with HIV, accounting for 25% of HIV-related deaths among HIV positive people.

TB is an opportunistic infection that more easily takes hold in individuals with weakened immune systems. An individual living with HIV is 20 to 30 times more likely to develop TB than an uninfected...

March 23, 2017
New Multi-site Phase 2 Ebola Vaccine Study Begins in Africa

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected volunteers. The multisite study began today with its first vaccination in Uganda. The trial will also take place in Nigeria, Kenya, Tanzania and...